BABA vs IP

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

The deterministic health profile is severely compromised, highlighted by a Piotroski F-Score of 2/9, indicating weak financial health and deteriorating fundamentals. While revenue growth appears strong at 53.10%, this has not translated to the bottom line, as evidenced by a negative profit margin of -14.88% and a staggering -300% YoY EPS growth. The dividend is currently unsustainable with a payout ratio of 158.12%, signaling a high risk of a dividend cut. Technicals are completely bearish (0/100), and the stock is trading near its 52-week low despite optimistic analyst targets.